SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mark Solutions Inc – ‘424B2’ on 8/7/96

As of:  Wednesday, 8/7/96   ·   Accession #:  889812-96-1033   ·   File #:  33-92166

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 8/07/96  Mark Solutions Inc                424B2                  1:64K                                    Global Fin’l Press/NY/FA

Prospectus   —   Rule 424(b)(2)
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 424B2       Prospectus                                            32    113K 


Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
"Class A Warrants
"Finance Warrants
"Consultant Warrants
2Miscellaneous Warrants
3Available Information
4Incorporation of Certain Documents by Reference
6Summary
"The Company
"Risk Factors
7Certain Information about Outstanding Equity Securities of Mark
8Summary Selected Financial Data
12Dilution
"Dividend Policy
13Use of Proceeds
"Capitalization
14Price Range of Common Stock and Class A Warrants
15Selected Financial Data
16Business
18Historical Development
20MarkCare Medical Systems, Inc
23Management
25Security Ownership of Certain Beneficial Owners and Management
27Selling Shareholders
"Certain Outstanding Warrants
28Private Placement Warrants
29Employee/Directors Warrants
30Plan of Distribution
31Description of Securities
"Common Stock
32Legal Matters
"Experts
424B21st Page of 32TOCTopPreviousNextBottomJust 1st
 

Registration Statement No. 33-92166 Rule 424 (b)(2) Prospectus Prospectus MARK SOLUTIONS, INC. 4,588,170 Shares of Common Stock This prospectus is being delivered to holders of the warrants to purchase shares of common stock, $.01 par value (the "Common Stock") of Mark Solutions, Inc. ("Mark") described below. Mark is offering up to 375,600 shares to holders of the Class A Warrants pursuant to the exercise of such warrants. In addition, of the shares of Common Stock being offered by this prospectus, 4,212,570 shares may be sold by selling shareholders including 2,993,280 shares which may be acquired by the selling shareholders pursuant to the exercise of outstanding warrants. See "Selling Shareholders" and "Certain Outstanding Warrants". The Selling Shareholders may sell such shares in the open market or in privately negotiated transactions. While Mark will receive proceeds from the exercise of the Warrants, Mark will receive no proceeds from the resale of Common Stock by the Selling Shareholders. All of the foregoing shares have been registered under prior registration statements. Mark currently has 4,300,880 shares of Common Stock underlying outstanding warrants, of which 3,308,880 are registered pursuant to registration statements of which this prospectus forms a part. Mark registered these shares pursuant to agreements and understandings with the holders of the Warrants. The registration of the Common Stock underlying the Warrants will facilitate the exercise of the Warrants. To the extent the Warrants are exercised, Mark will receive proceeds for working capital purposes. Class A Warrants. The 375,600 outstanding redeemable common stock purchase warrants expiring on December 31, 1996 (the "Class A Warrants"). Each Class A Warrant represents the rights to purchase one share of Common Stock at a price of $3.25 per share. Finance Warrants. The 1,446,158 outstanding common stock purchase warrants (the "Finance Warrants") which were issued in connection with debt and equity financings of Mark. The Finance Warrants expire on various dates beginning January 15, 1997 and ending May 16, 1998 and each represents the right to purchase one share of Common Stock at a price ranging from $ 2.50 to $ 15.00. Consultant Warrants. The 685,000 outstanding common stock purchase warrants (the "Consultant Warrants") which were issued to consultants. The Consultant Warrants expire on various dates beginning August 8, 1996 and ending May 8, 1997 and each represents the right to purchase one share of Common Stock at a price ranging from $ 2.00 to $ 10.00. -1-
424B22nd Page of 32TOC1stPreviousNextBottomJust 2nd
Private Placement Warrants. The 198,572 outstanding common stock purchase warrants (the "Private Placement Warrants") which were issued in connection with Mark's unit offering in January and February 1995. The Private Placement Warrants expire on February 14, 1997 and each represents the right to purchase one share of Common Stock at a price of $ 2.00. Employee/Director Warrants. The 154,383 outstanding common stock purchase warrants (the "Employee/Director Warrants") which were issued to employees and outside directors of Mark. The Employee/ Director Warrants expire on various dates beginning April 25, 1997 and ending September 21, 1997 and each represents the right to purchase one share of Common Stock at a price ranging from $ 3.25 to $ 4.50. Miscellaneous Warrants. The 449,167 outstanding common stock purchase warrants (the "Miscellaneous Warrants") issued in other business transactions. The Miscellaneous Warrants expire on various dates beginning November 3, 1996 and ending August 17, 1998 and each represents the right to purchase one share of Common Stock at a price ranging from $ 2.625 to $10.50 per share. The Class A Warrants, Note Warrants, Finance Warrants, Consultant Warrants, Private Placement Warrants, Employee/Director Warrants and Miscellaneous Warrants are collectively referred to as the "Warrants". THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK AND SUBSTANTIAL DILUTION. See "Risk Factors" and "Dilution". The Common Stock is traded on NASDAQ Small Cap Market under the symbol "MCSI". The Class A Warrants are traded in the over-the-counter market and are quoted in the National Daily Quotation Sheets. On July 31, 1996, the closing price of the Common Stock and Class A Warrants was $ 5-1/2 per share. There has been no reported trade in the Class A Warrants since February 13, 1996. THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. ----------------------------------------------- The date of this Prospectus is July 31, 1996. -2-
424B23rd Page of 32TOC1stPreviousNextBottomJust 3rd
No person is authorized to give any information or to make any representations other than those contained in this Prospectus, and, if given or made, such information or representations should not be relied upon as having been authorized. This Prospectus does not constitute an offer to sell, or solicitation of an offer to purchase, the securities offered by this Prospectus, in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. Neither the delivery of this Prospectus nor any distribution of the securities being offered pursuant to this Prospectus shall, under any circumstances, create an implication that there has been no change in the information set forth herein since the date of this Prospectus. AVAILABLE INFORMATION Mark has filed with the Commission a Registration Statement on Form S-3 (together with all amendments and exhibits thereto the "Registration Statement") under the Securities Act with respect to the Common Stock offered hereby. As permitted by the rules and regulations of the Commission, this Prospectus omits certain information contained in the Registration Statement. For such information, reference is made to the Registration Statement and the exhibits thereto. Mark is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance therewith Mark files reports and other information with the Commission. The Registration Statement, reports and other information filed by Mark with the Commission can be inspected and copied at the public reference facilities maintained by the Commission at Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549, and at the Commission's Regional Offices at 7 World Trade Center, Suite 1300, New York, New York 10048, 1401 Brickell Avenue, Suite 200, Miami, Florida 33131, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661, 1801 California Street, Suite 4800, Denver Colorado 80202 and 5670 Wilshire Boulevard, 11th Floor, Los Angeles, California 90036. Copies of such material also can be obtained from the Public Reference Section of the Commission, Washington, D.C. 20549 at prescribed rates. -3-
424B24th Page of 32TOC1stPreviousNextBottomJust 4th
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE The following documents previously filed by Mark with the Commission pursuant to the Exchange Act are incorporated and made a part of this Prospectus by reference: (1) Mark's Annual Report on Form 10-K for the year ended June 30, 1995; (2) Mark's Quarterly Reports on Form 10-Q for the quarters ended September 30, 1995, December 31, 1995 and March 31, 1996; (3) Mark's Current Report on Form 8-K dated October 13, 1995; (4) Mark's Current Report on Form 8-K dated May 28, 1996; and (5) The description of the Common Stock contained in the Registration Statement on Form 8-A. All documents filed by Mark pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Prospectus and prior to the termination of the offering contemplated by his Prospectus shall be deemed to be incorporated by reference into this Prospectus and to be a part hereof from the date of filing such documents. Any statements contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Prospectus to the extent that a statement contained herein or in any subsequently filed documents which also is or is deemed to be incorporated by reference herein modified or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus. Mark undertakes to provide without charge to each person, including any beneficial owner, to whom a copy of this Prospectus has been delivered, on written or oral request of any such person, a copy of any or all of the documents referred to above which have been or may be incorporated by reference in the Prospectus, other than exhibits to such documents (unless such documents are specifically incorporated by reference in such documents). Requests for such copies should be directed to Ms. Cheryl Gomes, Mark Solutions, Inc., 1515 Broad Street, Bloomfield, New Jersey 07003, Telephone Number (201) 893-0500. -4-
424B25th Page of 32TOC1stPreviousNextBottomJust 5th
TABLE OF CONTENTS Page ---- Available Information . . . . . . . . . . . . . . . . . . 3 Incorporation of Certain Documents by Reference . . . . . 4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . 6 The Company . . . . . . . . . . . . . . . . . . . . . 6 Risk Factors. . . . . . . . . . . . . . . . . . . . . 6 Certain Information about Outstanding Equity Securities of Mark. . . . . . . . . . . . . . 7 Summary Selected Financial Data . . . . . . . . . . . 8 Risk Factors. . . . . . . . . . . . . . . . . . . . . . . 9 Dilution. . . . . . . . . . . . . . . . . . . . . . . . . 12 Dividend Policy . . . . . . . . . . . . . . . . . . . . . 12 Use of Proceeds . . . . . . . . . . . . . . . . . . . . . 13 Capitalization. . . . . . . . . . . . . . . . . . . . . . 13 Price Range of Common Stock and Class A Warrants. . . . . 14 Selected Financial Data . . . . . . . . . . . . . . . . . 15 Business . . . . . . . . . . . . . . . . . . . . . . . . 16 Management . . . . . . . . . . . . . . . . . . . . . . . 23 Security Ownership of Certain Beneficial Owners and Management . . . . . . . . . . . . . . . . . . . . . 25 Selling Shareholders . . . . . . . . . . . . . . . . . . 27 Certain Outstanding Warrants . . . . . . . . . . . . . . 27 Plan of Distribution . . . . . . . . . . . . . . . . . . 30 Description of Securities . . . . . . . . . . . . . . . . 31 Legal Matters . . . . . . . . . . . . . . . . . . . . . . 32 Experts . . . . . . . . . . . . . . . . . . . . . . . . . 32 -5-
424B26th Page of 32TOC1stPreviousNextBottomJust 6th
SUMMARY The following is a summary of certain information contained in this Prospectus. This summary is qualified in its entirety by the more detailed information and financial statements appearing elsewhere in this Prospectus and the exhibits hereto. Certain capitalized items used and not otherwise defined in this summary have the meanings ascribed to them elsewhere in this Prospectus. THE COMPANY Mark Solutions, Inc. ("Mark") is a Delaware corporation which operates its various businesses through wholly-owned subsidiaries and a division. Mark is engaged in the design, manufacture, assembly and/or distribution of (i) modular steel cells for housing of the general prison population as well as for use as infectious disease isolation units for correctional institutions and health care facilities, (ii) a treatment booth for communicable diseases and (iii) diagnostic support and archiving computer systems marketed under the name "IntraScan". Mark has succeeded to the businesses of Mark Correctional Systems, Inc. under a reorganization (the "Reorganization") consummated on November 10, 1993 pursuant to an Agreement and Plan of Reorganization dated December 23, 1992, as amended. Mark was incorporated under the laws of the State of Delaware on September 29, 1986 under the name "Showcase Cosmetics, Inc." Mark's principal executive office is located at Parkway Technical Center, 1515 Broad Street, Bloomfield, New Jersey 07003 and its telephone number is (201) 893-0500. RISK FACTORS The securities of Mark involve a high degree of risk. Mark has experienced operating losses and related working capital deficiencies over the past several years. In addition, the success of Mark will be primarily dependent on the sale of its modular steel products which have been subject to sporadic sales. See "Risk Factors". -6-
424B27th Page of 32TOC1stPreviousNextBottomJust 7th
CERTAIN INFORMATION ABOUT OUTSTANDING EQUITY SECURITIES OF MARK Common Stock ............................ 13,372,463 shares Class A Warrants ........................ 375,600 warrants Finance Warrants(1) ..................... 1,446,158 warrants Consultant Warrants(2) .................. 685,000 warrants Private Placement Warrants .............. 198,572 warrants Employee/Director Warrants(3) ........... 154,383 warrants Miscellaneous Warrants(4) ............... 449,167 warrants Other Warrants/Options(5) ............... 992,000 warrants ----------- (1) Of such warrants 1,150,000 are exercisable at $ 4.25 per share; 200,000 are exercisable at $ 2.50 per share; 70,000 are exercisable at $ 3.75 per share and 26,158 are exercisable at $ 15.00 per share. (2) Of such warrants 410,000 are exercisable at $ 5.00 per share; 200,000 are exercisable at $ 2.00 per share; 50,000 are exercisable at $ 3.00 per share and 25,000 are exercisable at $ 7.50 per share. (3) Of such warrants 151,050 are exercisable at $ 3.25 per share and 3,333 are exercisable at $ 4.50 per share. (4) Of such warrants 250,000 are exercisable at $ 4.25 per share; 150,000 are exercisable at $ 2.625 per share; 42,500 are exercisable at $ 3.25 per share and 6,667 are exercisable at $ 10.50 per share. (5) Of such warrants 305,000 are exercisable at $ 5.375 per share; 222,500 are exercisable at $ 4.00 per share; 144,500 are exercisable at $ 3.25 per share; 125,000 are exercisable at $ 6.00 per share; 100,000 are exercisable at $ 5.625 per share; 75,000 are exercisable at $ 5.50 per share; 10,000 are exercisable at $ 6.375 per share and 10,000 are exercisable at $ 4.25 per share. -7-
424B28th Page of 32TOC1stPreviousNextBottomJust 8th
SUMMARY SELECTED FINANCIAL DATA The following summary selected financial is based upon financial statements incorporated herein and such summary information should be read in conjunction with such financial statements and notes thereto. Income Statement Data: [Enlarge/Download Table] Nine Months Ended March 31 Fiscal Years Ended June 30 1996 1995 1995 1994 1993 --------------------------- ------------------------------------------- Revenues $ 3,206,371 $ 2,749,847 $ 6,125,573 $ 3,183,073 $ 5,309,660 Costs and Expenses 6,464,898 5,228,489 10,952,303 7,033,374 6,634,648 (Loss) From Continuing Operations (3,306,705) (2,472,656) (4,826,730) (3,915,050) (1,324,988) (Loss) From Discontinued Operations (104,503) (111,841) (277,438) (193,620) -- Net Income (Loss) (3,411,208) (2,584,497) (5,190,073) (4,138,130) (1,587,197) Earnings (Loss) per Share ($.27) ($.25) ($.48) ($.47) ($.18) Weighted Average Shares Outstanding 12,500,250 10,418,715 10,726,204 8,802,543 8,710,975 Balance Sheet Data: At March 31 At June 30 1996 1995 ---------- ---------- Working Capital (Deficit) $ 796,931 $ (48,112) Total Assets 3,145,428 3,978,383 Total Liabilities 1,134,190 2,189,322 Stockholders' Equity 2,011,238 1,789,061 -8-
424B29th Page of 32TOC1stPreviousNextBottomJust 9th
RISK FACTORS Prospective investors in the Common Stock should give careful consideration to the following risks in making a decision concerning the securities offered hereby. 1. Poor Financial Condition; Going Concern Opinion. Mark has experienced significant operating losses and working capital and liquidity deficiencies over the past several years. Mark had net losses of $ 5,190,073 and $ 3,411,208 for the fiscal year ended June 30, 1995 and the nine months ended March 31, 1996. In addition, Mark had an accumulated deficit of $ 20,512,806 at March 31, 1996. Mark has and will continue to experience such financial difficulties in the foreseeable future absent significant increases in the sale of modular cells, its principal product. Accordingly, based on past operating results there can be no assurance that Mark will be able to operate profitably. The report of the independent certified public accountants for the fiscal year ended June 30, 1995 includes an explanatory paragraph regarding substantial doubt about Mark's ability to continue as a going concern due to the recurring losses from operations. Mark's poor financial condition could adversely effect its ability to raise additional working capital pursuant to private sales of its securities. 2. Limited Market; Contracts for Modular Cells. Mark has derived substantially all of its revenue from the sale of its modular cells and disease containment units to correctional institutions and management believes that the sale of these products will continue to represent virtually all of Mark's operating revenues through December 31, 1996. The correctional institution market presents substantial sales obstacles. Unless the project is very small, correctional institutions, like other government agencies, must submit proposed projects to public bidding by prospective suppliers. The purchasing agency is obligated to select from among the bidders based on objective criteria. On the other hand, private purchasers generally do not require bidding and a vendor such as Mark would have the opportunity to convince the purchaser to deal with Mark to the exclusion of competitors. Mark continually bids on and solicits joint venture opportunities regarding construction projects utilizing its modular steel cell products. Mark currently has contracts for it modular cells aggregating $ 1,984,505 in revenue. 3. Working Capital Requirements. The ultimate success of Mark may depend upon its ability to raise additional equity or obtain debt financing until it can improve its operating results. To date Mark has primarily met its working capital requirements by the private issuance of its securities. Absent significant -9-
424B210th Page of 32TOC1stPreviousNextBottomJust 10th
proceeds from the exercise of Warrants and improvement in the operations of Mark, management believes that its present available working capital will be utilized by September 30, 1996. Mark has been unable to secure commercial and bank financing. In the event Mark must seek other sources of working capital, it will most likely have to rely on additional private sales of its equity or debt securities. While Mark has been successful in raising working capital through private sources in the past, no assurance can be given that such sources will be available, or, if available, on terms satisfactory to Mark. In the event Warrants are not exercised, Mark will look to the private placement of its securities both domestically and through Regulation S offerings to foreign investors, which in the past have been at discounts to the market price of the Common Stock and would result in dilution of the ownership of existing securityholders. Mark will initially look to the exercise of the Warrants for working capital. Therefore no significant efforts have been made to raise additional capital pursuant to the private sale of securities; however if sufficient Warrants are not exercised, Mark will attempt to effect such placements in August 1996. If adequate working capital financing is not secured, Mark will reduce overhead and personnel expenses and review its options regarding the sale or suspension of some of its product lines. 4. Competition. The construction industry in general and the government construction industry in particular are highly competitive. Due to the use of concrete and other traditional construction methods in the substantial majority (approximately 95%) of correctional facility construction, Mark competes for market share with a number of major construction companies. Such competition is not with respect to any particular project, but in efforts to convince the purchasing agency to utilize steel cell construction rather than traditional methods. With respect to those projects which incorporate modular steel cell specifications in its design criteria, other companies are beginning to enter the field. Some of these companies have greater financial resources than Mark. In addition, a number of manufacturers which have greater financial and marketing resources than Mark, and which currently produce sheet metal products, could ultimately enter the modular cell business in competition with Mark. Accordingly, there can be no assurance that Mark will be able to successfully compete in the market for modular steel cells, which are Mark's most significant product. 5. Dependence on Key Person. Mark is dependent upon the continued services of Carl C. Coppola, its Chairman of the Board, President and Chief Executive Officer. The loss of Mr. Coppola could have a material adverse effect on Mark. Mark is the beneficiary of a term life insurance policy of $1,000,000 on the life of Mr. Coppola. -10-
424B211th Page of 32TOC1stPreviousNextBottomJust 11th
6. Bonding Qualifications. In connection with some government construction projects, Mark is required to provide performance and completion bonds as a condition to submission or participation in a bid. Due to Mark's financial condition, it has experienced difficulty in obtaining such bonds and obtained the required bonds for its only modular cell project through the assistance and guarantee of another business entity owned by an outside director. To date Mark has not limited its bidding activity nor lost any projects due to its limited bonding capacity. However, as Mark is awarded multiple projects, the inability to obtain bonds may limit the number of additional projects Mark can pursue and have a material adverse effect on the operations of Mark. 7. Subcontractor Credit Risk. Mark's manufacturing operations are limited to the steel modular cell for use as one component of correctional institution projects. Therefore, Mark may not be the prime contractor on a project, but a subcontractor. Under these circumstances, Mark usually will not have the direct financial obligation of the government agency or other purchaser, but will be primarily relying on the prime contractor regarding payment for its products. This presents a greater credit risk to Mark. 8. Related Party Transactions. Mark has been a party to business transactions with certain officers, Directors or their affiliates. Mark intends to purchase goods and services in the ordinary course of business from related parties and may determine based upon circumstances at that time to engage in additional transactions with officers, Directors, principal shareholders or affiliates. While Mark believes these transactions have been on terms no less favorable than could be obtained from unaffiliated parties, such situations present potential conflicts of interest. 9. No Dividends. Mark has never paid a cash dividend on its Common Stock. Mark does not intend to pay in the foreseeable future, cash dividends on the Common Stock but intends to retain its earnings to finance growth. 10. Dilution on Exercise of Warrants. Assuming full exercise of the Warrants to which this Prospectus relates certain of the holders of the Warrants will incur an immediate dilution in tangible book value of between $ 1.17 (59%) and $ 14.17 (94%) of the exercise price. See "Dilution". -11-
424B212th Page of 32TOC1stPreviousNextBottomJust 12th
DILUTION Dilution is a reduction in the value of the warrantholder's investment measured by the difference between the exercise price and the book value of a share of Common Stock. Book value is equal to stockholders' equity applicable to Common Stock as shown on Mark's balance sheet divided by the number of shares outstanding. At March 31, 1996, Mark had a tangible book value of $ .08 per share. A person exercising a Warrant will incur dilution to the extent that the exercise price exceeds the tangible book value (offset by any increase in book value due to the exercise of Warrants). Assuming full exercise of the Warrants to which this Prospectus relates, at March 31, 1996 Mark would have a tangible book value of $ .83 per share. The following table sets forth the range of immediate dilution in tangible book value which would be incurred by the holders of the Warrants. Percentage of Warrant Per Share Dilution Dilution from Exercise Price per Share Exercise Price ----------------- --------- -------------- $ 2.00 $ 1.17 59% 3.00 2.17 72 4.00 3.17 79 7.50 6.67 89 10.00 9.17 92 15.00 14.17 94 DIVIDEND POLICY Mark anticipates that for the foreseeable future it will not pay any cash dividends on its Common Stock and will continue to retain earnings, if any, for use in its business. Future dividend policy, however, will be determined by the Board of Directors based upon conditions then existing, including Mark's earnings and financial condition, capital requirements and other relevant factors. -12-
424B213th Page of 32TOC1stPreviousNextBottomJust 13th
USE OF PROCEEDS The net proceeds, if any, to be received by Mark from the exercise of the Warrants, after paying fees and expenses estimated to be approximately $ 40,000 will be used to the extent available for general corporate purposes, including working capital. The primary use of these proceeds will be to fund the selling, general and administrative expenses as well as to finance new projects if and when awarded. Pending utilization, Mark may invest the proceeds received in certificates of deposit or other short-term interest bearing securities. CAPITALIZATION The following table sets forth the capitalization of Mark on March 31, 1996. March 31 1996 ---------- Short-term obligations ................ $ -0- Current maturities of long-term obligations ............... 10,868 ---------- Current portion of obligations under capital lease .................. 5,584 ---------- Total short-term obligations ........ $ 16,452 ---------- Long-term obligations, excluding current maturities .................. $ 22,882 Long-term portion of obligations under capital lease .................. $ 31,920 ---------- Total long-term obligations ......... $ 54,802 ---------- Stockholders' equity: Common Stock: $.01 par value; 25,000,000 shares authorized; 13,085,465 shares outstanding(1)...... 130,853 Additional paid-in capital........... 22,393,191 Retained earnings (deficit).......... (20,512,806) ------------ Total stockholders' equity......... 2,011,238 ---------- Total short-term obligations, long-term obligations and stockholders' equity............................... $2,082,492 ========== ---------- (1) Does not include 4,300,880 shares reserved for issuance upon exercise of outstanding warrants and options including the Warrants. -13-
424B214th Page of 32TOC1stPreviousNextBottomJust 14th
PRICE RANGE OF COMMON STOCK AND CLASS A WARRANTS The following table sets forth for the calendar quarters indicated the high and low bid prices of Mark's Common Stock and Class A Warrants. The Common Stock trades on the NASDAQ system, Small Cap market. The Class A Warrants trade in the over-the-counter market bulletin board and pink sheets. Common Stock Class A Warrants High Low High Low ------ ----- ------ ----- 1994 1st Quarter 9 3-3/4 3/8 3/8 2nd Quarter 6 3 3/8 3/8 3rd Quarter 4-3/8 3-1/4 3/8 3/8 4th Quarter 3-7/8 2-1/2 3/8 3/8 1995 1st Quarter 4-1/8 2 3/8 3/8 2nd Quarter 5-1/2 3-1/4 3/8 3/8 3rd Quarter 8-7/8 5-3/8 3-5/8 1-7/8 4th Quarter 8 5-1/4 4 2-1/2 1996 1st Quarter 8-1/4 5-1/2 3-1/2 3-1/4 2nd Quarter 8-3/8 5-1/4 3-5/8 3-1/8 3rd Quarter (thru July 31) 6-5/8 5-1/8 2-7/8 1-1/8 On July 31, 1996 the closing bid and asked prices for the Common Stock were $ 5-3/8 and $ 5-1/2 per share, respectively and the closing bid and asked prices for the Class A Warrants was $ 2 per warrant. Over-the-counter quotations reflect inter-dealer prices without retail mark-up, mark-down or commission and do not necessarily represent actual transactions. As of July 31, 1996, there were 166 holders of record of the Common Stock and one holder of record of the Class A Warrants. There are 14 market makers in the Common Stock. -14-
424B215th Page of 32TOC1stPreviousNextBottomJust 15th
SELECTED FINANCIAL DATA The following Selected Financial Data is based upon financial statements incorporated herein and such information should be read in conjunction with such financial statements and notes thereto. Income Statement Data: [Enlarge/Download Table] Nine Months Ended March 31 Fiscal Years Ended June 30 ------------ -------------------------- 1996 1995 1995 1994 1993 1992 1991 -------------------------- ----------------------------------------------------------------------- Revenues $3,206,371 $2,749,847 $6,125,573 $3,183,073 $5,309,660 $3,894,602 $492,348 ----------- ----------- ----------- ----------- ----------- ----------- ----------- Costs and Expenses: Cost of Sales 3,656,949 2,462,786 5,975,973 2,370,971 3,742,371 3,010,765 551,815 Selling, general & administrative 2,807,949 2,761,765 3,872,392 3,592,081 2,334,159 1,271,725 858,909 Research & development -- 3,938 3,938 270,322 558,118 -- 386,600 Reduction of carrying value of assets -- -- 1,100,000 800,000 -- -- -- Total Costs & Expenses 6,464,898 5,228,489 10,952,303 7,033,374 6,634,648 4,282,490 1,797,324 ----------- ----------- ----------- ----------- ----------- ----------- ----------- Operating Income (Loss) (3,258,527) (2,478,642) (4,826,730) (3,850,301) (1,324,988) (387,888) (1,304,976) ----------- ----------- ----------- ----------- ----------- ----------- ----------- Net Other Income (Expense) (48,178) 5,986 (85,905) (64,749) (262,209) (135,691) (181,018) (Loss) From Continuing Operations (3,306,705) (2,472,656) (4,912,635) (3,915,050) (1,587,197) (523,579) (1,485,994) (Loss) From Discontinued Operations (104,503) (111,841) (277,438) (193,620) -- -- -- Income Tax -- -- -- 29,460 -- -- -- Net Income (Loss) ($3,411,208) ($2,584,497) ($5,190,073) ($4,138,130) ($1,587,197) ($523,579) ($1,485,994) =========== =========== =========== =========== =========== =========== =========== Earnings (Loss) per Share: ($.27) ($.25) ($.48) ($.47) ($.18) ($.06) ($.17) Weighted Average Shares Outstanding 12,500,250 10,418,715 10,726,204 8,802,543 8,710,975 8,710,975 8,710,975 Balance Sheet Data: [Enlarge/Download Table] At March 31, At June 30, 1996 1995 1994 1993 1992 1991 ---------- ------------------------------------------------------------ Working Capital (Deficit) $ 796,931 $ (48,112) $ 216,635 $ 379,484 $ 629,424 ($2,768,906) Net Property & Equipment 256,887 318,491 369,939 503,112 473,111 663,816 Total Assets 3,145,428 3,978,383 4,953,651 4,460,174 2,096,427 938,759 Current Liabilities 1,079,388 2,169,657 909,693 938,603 958,065 3,007,272 Other Liabilities 54,802 19,665 8,313 16,377 2,194,591 218,874 Stockholders' Equity (Impairment) 2,011,238 1,789,061 4,035,645 3,505,194 (1,056,229) (2,287,387) -15-
424B216th Page of 32TOC1stPreviousNextBottomJust 16th
BUSINESS General Mark Solutions, Inc. ("Mark") is a Delaware corporation which operates its various businesses through wholly-owned subsidiaries and a division. Mark is engaged in the design, manufacture, assembly and/or distribution of (i) modular steel cells for housing of the general prison population as well as for use as infectious disease isolation units for correctional institutions and healthcare facilities, (ii) a treatment booth for communicable diseases and (iii) diagnostic support and archiving computer systems marketed under the name "IntraScan". Mark's modular cells meet or exceed all applicable building and safety code requirements in the United States and can be manufactured and installed more efficiently than traditional housing alternatives by virtue of lower labor and construction costs and shorter installation time. Management also believes that its prefabricated modular cell manufacturing process has other applications such as temporary emergency housing and permanent shelters, although no assurances can be given that such applications will be successfully developed and marketed. Management believes that continued nationwide judicial and legislative emphasis on an expedient easing of the overcrowding conditions of correctional institutions, as well as the increase in the demand for isolation and treatment quarters for both correctional institutions and healthcare facilities, due to the rise in communicable diseases such as tuberculosis and the HIV virus, present a significant growth opportunity for Mark. However, there can be no assurance that any such business will develop. Mark was incorporated under the laws of the State of Delaware on September 29, 1986 under the name "Showcase Cosmetics, Inc." Mark's principal executive office is located at Parkway Technical Center 1515 Broad Street, Bloomfield, New Jersey 07003 and its telephone number is (201) 893-0500. -16-
424B217th Page of 32TOC1stPreviousNextBottomJust 17th
Industry and Segment Financial Data The following table sets forth information regarding Mark's industry segments and classes of products. Prior to the fiscal year ended June 30, 1994, Mark derived substantially all of its revenues from the sale of its modular steel cell products. Accordingly, no financial information about industry segments is presented for prior periods. On October 10, 1995, Mark sold its Bar-Lor Cosmetics business. See "Historical Development". Fiscal Year Ended June 30, 1995 1994 ---------- ---------- Sales to unaffiliated customers: Mark Correctional Systems: Modular Cells ............ $5,949,490 $2,839,052 MarkCare Medical Systems: IntraScan ................ $ 15,000 $ 137,512 Treatment Booths ......... $ 161,083 $ 206,509 $ 176,083 $ 344,021 ---------- ---------- Bar-Lor Cosmetics ............ $ 917,934 $ 812,374 Operating Loss: Mark Correctional Systems .... ($3,055,631) ($ 2,454,292) MarkCare Medical Systems ..... ($ 671,099) ($ 582,592) Bar-Lor Cosmetics ......... ($1,370,537) ($ 1,008,269) Identifiable Assets: Mark Correctional Systems ..... $3,505,086 $ 3,047,154 MarkCare Medical Systems ...... $ 268,795 $ 340,238 Bar-Lor Cosmetics .......... $ 459,817 $ 1,864,438 -17-
424B218th Page of 32TOC1stPreviousNextBottomJust 18th
Historical Development Mark has succeeded to the businesses of Mark Correctional Systems, Inc., a Delaware corporation ("MCS") and Showcase Cosmetics, Inc., a Delaware corporation ("Showcase") under a reorganization (the "Reorganization") consummated on November 10, 1993 pursuant to an Agreement and Plan of Reorganization dated December 23, 1992, as amended. On September 24, 1992 MCS acquired all of the assets, subject to substantially all of the liabilities, of Mark Correctional Systems, Inc., a New Jersey corporation, ("MCS New Jersey") for approximately 80% of the outstanding Common Stock immediately after the asset purchase. On November 20, 1992 MCS acquired all of the capital stock of Diversified Imaging Technology Corporation, a Maryland corporation ("DIT"), which owned the rights to the IntraScan I system. DIT subsequently changed its name to "MarkCare Medical Systems, Inc." ("MarkCare"). On October 10, 1995, Mark sold its Bar-Lor Cosmetics business to Alan R. Steiner, president of the cosmetics subsidiaries, for $ 100,000 in cash. The sale was consummated pursuant to a stock purchase agreement whereby Mr. Steiner purchased all of the outstanding shares of three Mark subsidiaries, Bar-Lor Cosmetics, Ltd., Bar-Lor West, Inc. and Bar-Lor South, Inc. On May 28, 1996, Mark acquired all of the capital stock of Simis Medical Imaging, Limited, a privately held British company ("SMI") for $ 1,250,000 payable in Common Stock of Mark. At the initial closing, Mark issued an aggregate of 108,696 shares of Common Stock representing $ 625,000 of the purchase price. The balance of the purchase price will be paid in Common Stock on November 28, 1996 and the number of shares to be issued will be calculated by dividing $ 625,000 by the closing sales on November 25, 1996; provided, however, the maximum number of shares to be issued by Mark is 1,000,000. In addition, Christopher Cummins, one of the former shareholders of SMI has entered into a three-year employment agreement with SMI which provides for, among other things, (i) an annual salary of U.K. Pounds 60,000 in the initial year with U.K. Pound 5,000 increases in the succeeding two years and (ii) an annual bonus equal to 10% of the post tax profits of SMI. SMI is the developer of the IntraScan II software which Mark has been marketing under an exclusive dealer agreement covering North and South America. -18-
424B219th Page of 32TOC1stPreviousNextBottomJust 19th
Mark Correctional Systems Division Mark operates its modular steel cell and infectious disease isolation unit business through its division, Mark Correctional Systems. Modular Cells. Since the initial sale of its prefabricated modular steel cells for housing the general prison population in 1989, Mark has manufactured and sold 1,117 of its security prison cells for use in correctional institutions in 12 states including New York, New Jersey, Michigan, Missouri, Washington and Wisconsin. Mark's 616 cell project for the State Prison of Southern Michigan in Jackson, Michigan generated approximately $ 6,500,000 in revenue during the period of March through September 1995. In addition Mark has other uncompleted contracts for its modular cells aggregating $ 1,984,505. Other than as described above, Mark currently has no significant orders for the modular cells. Mark's modular cell is a prefabricated, installation-ready, lightweight steel structure which is manufactured according to the construction and security specifications of each correctional institution project in sizes from 60 to 100 square feet. Each modular cell can be equipped with lavatory facilities; wall-mounted sleeping accommodations; desk and stool; lighting and ventilation systems; and optional components such as fixed or operable windows and hinged or sliding security doors. Each modular cell is constructed of durable low maintenance, non-porous materials including a scratch resistant epoxy polymer finish and is acoustically and thermally insulated. The modular cell's lightweight construction requires less extensive and costly foundation work than a traditional (e.g. concrete) cell, and is designed with a self-contained exterior access panel which allows for simple ventilation, plumbing and electrical connections. Each cell is load-bearing to allow for multiple-story construction, and is manufactured to tolerances of 1/16 of an inch, which results in more efficient and faster on-site installation. Infectious Disease Isolation Units. Mark initially adapted its modular cell design to the manufacturing of infectious disease isolation units in 1992 for a court-ordered project at a New York City correctional institution on Rikers Island. Mark focuses its marketing efforts of infectious disease isolation units on correctional institutions and healthcare facilities. In addition to the modular cell features, the infectious disease isolation units are equipped with shower facilities and a -19-
424B220th Page of 32TOC1stPreviousNextBottomJust 20th
protective anteroom for healthcare providers and other individuals coming in contact with the occupant. To prevent the escape of contaminated air, each unit is equipped with a negative pressure ventilation system which safely discharges the air externally. Mark's epoxy polymer finish also allows for more effective sterilization and cleaning of the unit. Infectious disease isolation units are designed and manufactured according to the specific requirements of the project, including security requirements of correctional institutions. In addition, the units are subject to the guidelines and regulations of OSHA, NIOSH, the Centers for Disease Control and Prevention and applicable building codes including specific health guidelines which were established to provide effective treatment of the patient and the safety of medical providers including negative pressure requirements, filtration standards and air flow systems. MarkCare Medical Systems, Inc. Mark operates its healthcare products business through MarkCare Medical Systems, Inc., a wholly-owned Maryland subsidiary. Treatment Booths. Mark publicly introduced its first prototype general use treatment booth in August 1992. After design modifications were made to broaden its treatment capabilities, Mark began manufacturing operations in December 1992. The treatment booth is a single occupancy 70 cubic foot chamber used in the observation and treatment of patients with communicable diseases such as tuberculosis. The booth is designed to isolate patients in order to protect healthcare workers during sputum induction and to improve the efficacy of the dispensing of aerosolized drugs. In addition to incorporating the structural elements and low maintenance material of its modular cell technology, Mark equips the treatment booth with an air filtration system designed to provide for up to 450 air changes per hour through a laminar flow design which is monitored by a meter and alarm. The filtering process circulates air through a HEPA filter which collects 99.9% of all airborne particles including germs and medicines. The filtered air is then exposed to ultra-violet light for additional decontamination and is discharged externally. Mark has established safety and operational standards for its treatment booths based on recommendations from board certified hygienists and other medical professionals. Certification of booths is conducted by one of three independent laboratories for compliance with Mark's internal standards and manufacturers specifications. -20-
424B221st Page of 32TOC1stPreviousNextBottomJust 21st
IntraScan I. Mark instituted its marketing plan for the IntraScan I system, including its introduction at the Radiologist Society of North America exposition, in December 1992. IntraScan I is marketed to radiologists, gynecologists, urologists and small independent medical practices. The IntraScan I system is a computer-based diagnostic support product for use with all ultrasound equipment. IntraScan I is an archiving and image enhancing system which enables medical technicians to manipulate ultrasound images by enlarging and rotating images, as well as improving their clarity, sharpness and resolution. This results in improved diagnostic capabilities as compared to the images produced by ultrasound equipment alone. The information archiving applications of IntraScan I can be networked, allowing effective storage and transmission of information quickly between physicians and healthcare facilities through computer modems. The IntraScan I system consists of software programs protected by U.S. copyrights and standard hardware computer equipment as to which Mark has no proprietary interests. The computer hardware is comparable to a personal computer in size and user operation and interfaces with the IntraScan I software applications. The IntraScan I system is integrated and marketed in conjunction with the IntraScan II system. IntraScan II. From 1993 to May 1996, Mark marketed the IntraScan II "filmless" picture, archiving and communications system (PACS) under an exclusive software dealer agreement with SMI covering North and South America. On May 28, 1996, Mark acquired all of the capital stock of SMI for $ 1,250,000 payable in Common Stock of Mark. See "Historical Development". IntraScan II is marketed to radiology departments, large healthcare facilities, hospitals and outpatient imaging group practices. IntraScan II is a computer-based image, archival and retrieval system that interfaces with all medical imaging devices and can store and recall images in digital format from imaging modalities including x-ray, computed tomography (CAT Scan), computer radiology, nuclear medicine, ultra sound and magnetic resonance imaging (MRI). While Mark is aware of similar systems in various stages of development, management believes the IntraScan II is the only system which is designed to be open platform allowing the software to interface with most computer hardware and operating systems. -21-
424B222nd Page of 32TOC1stPreviousNextBottomJust 22nd
IntraScan II has a high resolution display capability (512 X 512 to 4000 X 4000 pixels). The high resolution allows medical providers to make diagnoses from computer digital images without the need for radiographic film. This capability eliminates the processing time for film development allowing faster diagnoses and significantly reduces the costs related to film development and patient record storage. The IntraScan II system allows image manipulation similar to the IntraScan I system, including simulation of the multi-image view box which allows side-by-side comparisons of images from different modalities (e.g. x-ray and CAT Scan). In addition, the IntraScan II system allows for networking between departments within a healthcare facility or between institutions at different locations by computer modems. This networking capability coupled with the high resolution allows efficient and instant transfer of diagnostic quality images for consultation and transportation of patient records. The IntraScan II system consists of software programs protected by British and United States copyrights and standard hardware computer equipment as to which Mark has no proprietary interests. -22-
424B223rd Page of 32TOC1stPreviousNextBottomJust 23rd
MANAGEMENT Directors And Executive Officers The following table sets forth the names and ages of the members of Mark's Board of Directors and its executive officers. Name Age Position ---- --- -------- Carl C. Coppola(1) 56 Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer Frederick M. Bolio 31 Vice President-Engineering and Manufacturing Michael J. Rosenberg 52 Vice President-Sales and Marketing; Richard Branca(2) 48 Director Ronald E. Olszowy 50 Director William Westerhoff(1) 59 Director Michael Nafash 35 Director ---------- (1) Member of the Compensation Committee (2) Member of the Audit Committee All directors hold office until the next annual meeting of shareholders of Mark (currently expected to be held during December 1996) and until their successors are elected and qualified. Officers hold office until the first meeting of directors following the annual meeting of shareholders and until their successors are elected and qualified, subject to earlier removal by the Board of Directors. -23-
424B224th Page of 32TOC1stPreviousNextBottomJust 24th
Carl C. Coppola has been a Director, President and Chief Executive Officer of Mark since November 10, 1993. Prior thereto and since 1984, Mr. Coppola served in the identical capacities for MCS, Mark's predecessor company. For more than 30 years, Mr. Coppola has been President and Chief Executive Officer of Mark Lighting Fixture Co., Inc., an unaffiliated entity. Frederick M. Bolio has been Vice President-Engineering and Manufacturing of Mark since June 23, 1994 and prior thereto was Engineering Manager of Mark since December 1991. From 1988 to November 1991 Mr. Bolio was Senior Engineer at Marino Industries Corp., a manufacturer of lightweight steel building products and components. Michael J. Rosenberg has been Vice President- Sales and Marketing of Mark and MCS since 1990. From December 1987 to 1989 served as President of Aloe Creme Laboratories, a cosmetics manufacturer. Richard Branca has been a Director of Mark and MCS since November 18, 1992. Since 1970 Mr. Branca has been President and Chief Executive Officer of Bergen Engineering Co., a construction company. Ronald E. Olszowy has been a Director of Mark and MCS since November 18, 1992. Since 1966, Mr. Olszowy has been President and Chief Executive Officer of Nationwide Bail Bonds, which provides bail, performance and fidelity bonds. Mr. Olszowy has also been President of Interstate Insurance Agency since 1980. William Westerhoff has been a Director of Mark and MCS since November 18, 1992. Mr. Westerhoff has been retired since June 1992. Prior thereto and for more than five years Mr. Westerhoff was, a partner of Sax, Macy, Fromm & Co., certified public accountants. Michael Nafash has been a Director of Mark since December 18, 1995. Mr. Nafash is Chairman of the Board, President and Chief Executive Officer of Evolutions, Inc. (OTC), an environmental oriented apparel company since February 1994. Since June 1992 Mr. Nafash has been employed, including as Chief Financial Officer from October 1993 to March 1995, by Pure Tech International, Inc. (NASDAQ/NMS:PURT), a plastics and metal recycling company. Prior thereto Mr. Nafash was a certified public accountant with Michaels, Nafash & Georgallas and Weidenbaum Ryder & Co. -24-
424B225th Page of 32TOC1stPreviousNextBottomJust 25th
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information with respect to each beneficial owner of 5% or more of the Common Stock, each Director of Mark, and all executive officers and Directors as a group as of July 31, 1996. The persons named in the table have sole voting and investment power with respect to all shares of Common Stock owned by them, unless otherwise noted. Number of % of Shares Shares Owned Outstanding ------------ ----------- Carl C. Coppola c/o Mark Solutions, Inc. 1515 Broad Street Bloomfield, NJ 07003 2,013,000(1) 14.8% Joseph Salvani 1 Duran Avenue Ridgewood, NJ 07450 1,159,956(2) 8.6 Walter Grossman 277 North Avenue Westport, CT 06880 862,713(3) 6.5 William Westerhoff 55,000(4) (5) Richard Branca 305,000(6) 2.2 Ronald E. Olszowy 105,000(4) (5) Michael Nafash 43,150(7) (5) All executive officers and Directors as a group (7 persons) 2,717,622(8) 19.3% -25-
424B226th Page of 32TOC1stPreviousNextBottomJust 26th
(1) Includes 89,800 shares held in trust for the benefit of children of Mr. Coppola. Mr. Coppola disclaims beneficial ownership of these shares. Also includes 200,000 shares of Common Stock issuable upon exercise of warrants which are presently exercisable. (2) Includes 150,000 shares of Common Stock issuable upon exercise of warrants which are presently exercisable. (3) Includes 112,000 shares held in trust for the benefit of two children of Mr. Grossman. Mr. Grossman disclaims beneficial ownership of these shares. (4) Represents or includes 55,000 shares of Common Stock issuable pursuant to options which are presently exercisable. (5) Less than 1% (6) Includes 205,000 warrants shares of Common Stock issuable pursuant to options and warrants which are presently exercisable. (7) Includes 17,150 shares of Common Stock owned by Evolutions, Inc., of which Mr. Nafash is Chairman, President and Chief Executive Officer. Mr. Nafash disclaims beneficial ownership of these shares. Includes 25,000 shares of Common Stock issuable upon exercise of warrants which are presently exercisable. (8) Includes 690,572 shares of Common Stock issuable upon exercise of warrants or options which are presently exercisable. -26-
424B227th Page of 32TOC1stPreviousNextBottomJust 27th
SELLING SHAREHOLDERS Of the 4,588,170 shares of Common Stock offered hereby, 1,279,290 are being offered for the accounts of the following persons: Securities Securities Owned to be Owned Before Securities After Name Offering to be Sold Offering(1) ------------------ ----------- ---------- ------------- Frank Brosens 22,800 22,800 0 Water Jel Technologies, Inc. 295,000 195,000 100,000 Joseph Salvani(2) 1,009,956 273,213 736,743 (5.5%) Walter Grossman(2) 750,713 273,213 477,500 (3.6%) Noam Gottesman 100,000 100,000 0 Darius Tencza 91,000 91,000 0 Richard Branca(3) 100,000 65,000 35,000 Joseph Salvani, Sr. 97,000 65,000 32,000 Edmund R. Miller 30,000 30,000 0 Frank Henry 82,144 57,144 25,000 Davis Weinstock II 205,000 76,760 128,240 Walter and Rebecca Schacht 35,160 30,160 5,000 ---------- (1) Percentage of outstanding shares of Common Stock (2) Principal Shareholder (3) Director of Mark CERTAIN OUTSTANDING WARRANTS Of the 4,588,170 shares of Common Stock offered hereby 2,933,280 may be offered by the following warrant holders subsequent to their purchase of shares of Common Stock from Mark pursuant to the exercise of Warrants. Number of Shares Subject Exercise Name to Warrants Price -------------------- -------------- -------- Finance Warrants Chester Daniel, Inc. 13,079 $ 15.00 Brookehill Equities, Inc. 13,079 15.00 Babystar, Inc. 1,000,000 4.25 Yitz Grossman 150,000 4.25 Yitz Grossman 70,000 3.75 Carl Coppola 200,000 2.50 Consultant Warrants Steven Markowitz 100,000 5.00 Joseph Sorbarra 100,000 5.00 Salvani Investments, Inc. 150,000 5.00 Cycle Contractors, Inc. 50,000 5.00 Aaron Lehman 25,000 7.50 Bertolini Printing, Inc. 10,000 5.00 AnReg Investment Corp. 200,000 2.00 Thomas Coughlin 50,000 3.00 -27-
424B228th Page of 32TOC1stPreviousNextBottomJust 28th
Private Placement Warrants Noam Gottesman 50,000 2.00 Jonathan Green 50,000 2.00 James R. Paradise 40,000 2.00 Edmund R. Miller 30,000 2.00 Frank Henry 28,572 2.00 Employee/Directors Warrants Richard Branca 30,000 3.25 Yitz Grossman 30,000 3.25 Ronald E. Olszowy 30,000 3.25 Simon Sinnreich 30,000 3.25 William Westerhoff 30,000 3.25 Alan Steiner 3,333 4.50 Michael Rosenberg 338 3.25 Leonid Futerman 239 3.25 John Reiling, Jr. 239 3.25 Frederick Bolio 234 3.25 Miscellaneous Warrants Theodore Meisel 15,000 3.25 LMD Industries Inc. 27,500 3.25 LMD Industries Inc. 6,667 10.50 Yitz Grossman 250,000 4.25 Bergen Engineering Co., Inc. 150,000 2.625 Finance Warrants In May 1993, Mark granted warrants to purchase shares of Common Stock to Chester Daniel Inc. and Brookehill Equities, Inc. as compensation for acting as placement agent for the private placement of Common Stock during April through June 1993 which raised gross proceeds of $ 1,961,850. In connection with a bridge loan of $ 1,500,000 made in October 1993 Mark granted Pure Tech, Babystar and Yitz Grossman warrants to purchase shares of Common Stock. Pure Tech subsequently transferred such warrants to Yitz Grossman. In connection with a bridge loan of $ 400,000 made in January 1995 Mark granted Carl Coppola warrants to purchase shares of Common Stock. Each of the foregoing issuances was effected in reliance of the registration exemption provided for by Section 4(2) of the Securities Act as not involving a public offering. Consultant Warrants On May 9, 1994 Mark granted to Steven Markowitz, Joseph Sobarra, Salvani Investments, Inc., Cycle Contractors, Inc., Aaron Lehman and Bertolini Printing, Inc. warrants to purchase shares of Common Stock as compensation for investment relations, financial advisory and marketing services. -28-
424B229th Page of 32TOC1stPreviousNextBottomJust 29th
On May 15, 1995 Mark granted to AnReg Investment Corp. warrants to purchase shares of Common Stock as compensation for product marketing services to be provided for a two-year period. On April 26, 1995 Mark granted to Thomas Coughlin warrants to purchase shares of Common Stock as partial compensation under a marketing consulting agreement terminable on 30-days' written notice. Pursuant to the consulting agreement, Mr. Coughlin will assist in the marketing of Mark's products primarily to the correctional industry. Each of the foregoing issuances was effected in reliance of the registration exemption provided for by Section 4(2) of the Securities Act as not involving a public offering. Private Placement Warrants In January through February 1995, Mark issued 641,549 warrants exercisable at $ 2.00 per share to investors in Mark's private placement of 641,549 Units consisting of two shares of Common Stock and one warrant which raised gross proceeds of $ 2,245,424. The sale of 511,549 of these Units was effected in reliance on the registration exemption provided by Section 4(2) of the Securities Act pursuant to Rule 506 of Regulation D. The sale of 130,000 of these Units was effected in reliance on Regulation S promulgated under the Act as an offering to non U.S. persons. Employee/Directors Warrants Each of Mark's nonemployee directors have been granted warrants to purchase an aggregate of 30,000 shares of Common Stock at $ 3.25 per share for serving in such capacity. Mark assumed warrants to purchase 3,333 shares of Common Stock at $4.50 per which were granted by its predecessor Showcase Cosmetics, Inc. On April 26, 1995 Mark granted five of its employees warrants to purchase shares of Common Stock as compensation for deferring an aggregate of $ 73,652 in salary for nine months. Miscellaneous Warrants On October 23, 1993, Pure Tech granted Mark the right of first refusal to manufacture and distribute a "reverse vending machine" for use in the disposal, redemption and recycling of recyclable containers in exchange for warrants to purchase 250,000 shares of Common Stock which are presently exercisable at $ 3.75 per share. Pure Tech subsequently transferred such warrants to Yitz Grossman. -29-
424B230th Page of 32TOC1stPreviousNextBottomJust 30th
In connection with Mark's Jackson, Michigan modular cell project, Bergen Engineering agreed to obtain and guarantee the necessary construction bonds through its bonding company. As partial compensation for providing this guarantee, Bergen Engineering received warrants to purchase shares of Common Stock at $ 2.625 per share. On August 17, 1993 Showcase Cosmetics, Inc. granted warrants to LMD Industries, Inc. to purchase 6,667 shares of Common Stock in consideration of a sale of $ 300,000 of inventory to Showcase Cosmetics, Inc. on highly favorable payment terms. Mark assumed these warrant pursuant to the Reorganization. On December 15, 1992 Mark granted warrants to purchase shares of Common Stock to Theodore Meisel and LMD Industries, Inc. as partial consideration for a 10% $ 500,000 senior secured loan to Mark which was repaid by June 15, 1993. Each of the foregoing issuances was effected in reliance of the registration exemption provided for by Section 4(2) of the Securities Act as not involving a public offering. PLAN OF DISTRIBUTION Of the 4,588,170 shares of Common Stock offered hereby, 4,212,570 are being offered for the accounts of the Selling Shareholders. Mark will not receive any proceeds from the sale of any shares of Common Stock by the Selling Shareholders. The sale of shares of Common Stock by the Selling Shareholders may be effected from time to time in transactions in the over-the-counter market, in negotiated transactions, through the timing of options on the shares or through a combination of such methods of sale, at fixed prices, which may be charged at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The Selling Shareholders may effect such transactions by selling the shares of Common Stock to or through broker-dealers, and such broker dealers may receive compensation in the form of discounts, concessions or commissions from the Selling Shareholders and/or the purchasers of the shares of Common Stock for which such broker-dealer may act as agent or to whom they sell as principal, or both (which compensation as to a particular broker-dealer may be in excess of customary compensation). The Selling Shareholders and any broker-dealers who act in connection with the sale of the shares of Common Stock hereunder may be deemed to be" underwriters" within the meaning of Section 2(11) of the Securities Act, and any commissions received by them and profit on any sale of the shares of Common Stock as principal might be deemed to be underwriting discounts and commissions under the Securities Act. -30-
424B231st Page of 32TOC1stPreviousNextBottomJust 31st
DESCRIPTION OF SECURITIES Common Stock Mark is authorized to issue 25,000,000 shares of common stock, par value $.01 per share of which 13,372,463 shares were outstanding as of June 30, 1996. The holders of Common Stock have one vote per share on all matters (including election of directors) without provision for cumulative voting. Thus, holders of more than 50% of the shares voting for the election of directors can elect all of the directors. The Common Stock is not redeemable and has no conversion or preemptive rights. The Common Stock currently outstanding is, and the Common Stock to be issued pursuant to the exercise of the Warrants will be, validly issued, fully paid and non-assessable. In the event of the liquidation of Mark, the holders of Common Stock will share equally in any balance of Mark's assets available for distribution to them after satisfaction of creditors and the holders of Mark's senior securities, if any. Class A Warrants Each Class A Warrant entitles the holder thereof to purchase one share of Common Stock until December 31, 1996 at a price of $3.25 per share. The Class A Warrants contain anti-dilution provisions regarding certain events, including but not limited to stock dividends, split-ups and reclassifications. Instructions pertaining to exercise of the Class A Warrants are provided on the warrant certificates. All or any portion of the Class A Warrants can be called for redemption by Mark at a redemption price of $.01 per warrant any time during their exercise term upon a minimum of 30 days' prior written notice mailed to the registered holders of the Class A Warrants, subject to the right of the holders to exercise their purchase rights between the date of any notice of redemption up to and including the redemption date given by Mark. Any holders who do not exercise their Class A Warrants prior to the date set for redemption will receive the redemption price and will forfeit their rights to purchase the Common Stock underlying the Class A Warrants. Mark may, in its sole discretion, extend the term of the Class A Warrants or reduce their exercise price, to the extent permitted by the Delaware General Corporation Law. Mark may not, however, raise the exercise price, except as required to reflect recapitalizations (e.g. reverse stock splits). Holders of the Class A Warrants do not have any of the rights or privileges of shareholders of Mark prior to the exercise of the warrants. -31-
424B2Last Page of 32TOC1stPreviousNextBottomJust 32nd
Other Warrants The exercise price and expiration dates of the other Warrants are set forth on the cover page of this Prospectus. Each of the Warrants contain anti-dilution provisions regarding certain events, including but not limited to stock dividends, split-ups and reclassifications. Holders of the Warrants do not have any of the rights or privileges of shareholders of Mark prior to the exercise of the warrants. Registration Requirements The Class A Warrants may not be exercised unless Mark has on file a current registration statement pertaining to the underlying Common Stock with the Commission. The remaining Warrants may be exercised at any time, however the sale of the Common Stock received upon exercise may only be sold pursuant to a current registration statement or an exemption from such registration requirements. Mark intends to use reasonable efforts to file post-effective amendments so that holders will not be precluded from exercising the Warrants and subsequently selling the underlying Common Stock. In the event that a post-effective amendment is not filed when required and the period for exercise of specific warrant is not extended, holders could be precluded from exercising their warrant and could be deprived of the opportunity to profit from increases, if any, in the market price of the Common Stock. Transfer Agent The Transfer Agent for the Common Stock and the Class A Warrants is Continental Stock Transfer & Trust Company, New York, New York. LEGAL MATTERS Timothy J. McCartney, Esq. has acted as counsel for Mark and has rendered an opinion on the validity of the shares of Common Stock to be issued upon exercise of the Warrants. EXPERTS Mark's consolidated balance sheets as of June 30, 1995 and 1994 and the consolidated statements of operations, stockholders' equity and cash flows for each of the three years in the period ended June 30, 1995 incorporated by reference in this Prospectus, have been incorporated herein in reliance on the report, which includes an explanatory paragraph regarding the substantial doubt about Mark's ability to continue as a going concern, of Sax Macy Fromm & Co., P.C., independent certified public accountants, given on the authority of that firm as experts in accounting and auditing. -32-

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘424B2’ Filing    Date First  Last      Other Filings
8/17/982
5/16/981
9/21/972
5/8/971
4/25/972
2/14/97210-Q
1/15/971
12/31/9613110-Q,  10-Q/A
11/28/9618
11/25/9618
11/3/962
9/30/961010-Q
8/8/961
Filed on:8/7/96
7/31/96225
6/30/963110-K,  10-K/A
5/28/964218-K,  8-K/A
3/31/9641310-Q
2/13/962
12/31/95410-Q
12/18/9524DEF 14A
10/13/9548-K
10/10/951718
9/30/95410-Q
6/30/95432
5/15/9529
4/26/9529
6/30/941732
6/23/9424
5/9/9428
11/10/93624
10/23/9329
8/17/9330
6/15/9330
12/23/92618
12/15/9230
11/20/9218
11/18/9224
9/24/9218
 List all Filings 
Top
Filing Submission 0000889812-96-001033   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 12:58:36.1am ET